Equities Analysts Set Expectations for Acorda Therapeutics Inc.’s Q3 2016 Earnings (ACOR)
Acorda Therapeutics Inc. (NASDAQ:ACOR) – Equities researchers at Leerink Swann issued their Q3 2016 EPS estimates for Acorda Therapeutics in a research report issued on Tuesday. Leerink Swann analyst P. Matteis expects that the firm will post earnings of ($0.36) per share for the quarter. Leerink Swann currently has a “Market Perform” rating and a $25.00 price target on the stock. Leerink Swann also issued estimates for Acorda Therapeutics’ Q4 2016 earnings at ($0.23) EPS, FY2016 earnings at ($1.04) EPS and FY2017 earnings at ($0.81) EPS.
Other research analysts have also issued reports about the company. Stifel Nicolaus reissued a “buy” rating on shares of Acorda Therapeutics in a report on Thursday, August 25th. Zacks Investment Research lowered Acorda Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, June 28th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Acorda Therapeutics in a report on Thursday, August 25th. Cowen and Company reaffirmed an “outperform” rating and set a $65.00 target price on shares of Acorda Therapeutics in a report on Thursday, August 25th. Finally, TheStreet lowered Acorda Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, July 28th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $39.63.
Acorda Therapeutics (NASDAQ:ACOR) traded down 4.25% during mid-day trading on Friday, reaching $19.83. The company’s stock had a trading volume of 258,056 shares. Acorda Therapeutics has a 12-month low of $19.82 and a 12-month high of $43.63. The firm’s 50 day moving average is $24.19 and its 200-day moving average is $25.84. The company’s market cap is $913.96 million.
Acorda Therapeutics (NASDAQ:ACOR) last released its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.18 by $0.11. Acorda Therapeutics had a positive return on equity of 1.00% and a negative net margin of 1.08%. The firm earned $127.45 million during the quarter, compared to the consensus estimate of $128.33 million. During the same period in the previous year, the firm earned $0.31 EPS. The business’s revenue was up 12.1% compared to the same quarter last year.
A number of institutional investors have recently modified their holdings of the company. Panagora Asset Management Inc. increased its position in shares of Acorda Therapeutics by 3.7% in the first quarter. Panagora Asset Management Inc. now owns 164,588 shares of the biopharmaceutical company’s stock worth $4,353,000 after buying an additional 5,808 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in Acorda Therapeutics during the first quarter valued at $291,000. Arrowgrass Capital Partners US LP purchased a new position in Acorda Therapeutics during the first quarter valued at $661,000. Jacobs Levy Equity Management Inc. purchased a new position in Acorda Therapeutics during the first quarter valued at $2,508,000. Finally, HBK Investments L P purchased a new position in Acorda Therapeutics during the first quarter valued at $1,108,000.
In other Acorda Therapeutics news, insider Jane Wasman sold 3,750 shares of the stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $20.78, for a total transaction of $77,925.00. Following the transaction, the insider now owns 105,021 shares in the company, valued at $2,182,336.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 8.00% of the company’s stock.
About Acorda Therapeutics
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza.
Receive News & Stock Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related stocks with our FREE daily email newsletter.